We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Data Further Suggest Possibility of Blood Test for Cancers

By LabMedica International staff writers
Posted on 05 Aug 2014
Print article
EKF Diagnostics\' PointMan technology for isolating and characterizing low-level DNA mutations in blood
PointMan technology for isolating and characterizing low-level DNA mutations in blood (Photo courtesy of EKF Diagnostics)
New results using an innovative DNA mutation enrichment technology suggest the possibility of a simple blood test for various cancers.

EKF Diagnostics (Cardiff, Wales, UK) has announced that the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea (UK) have continued to confirm the effectiveness of its PointMan technology for isolating and characterizing low-level DNA mutations in blood. Its sensitivity paves the way for the possibility of using a simple blood test to screen and diagnose different cancers, as well as monitor the efficacy of anticancer therapies.

Following work undertaken by the Swansea-based team earlier this year, which successfully detected circulating free DNA (cfDNA) mutations from melanoma patients using PointMan, further studies were carried out on blood samples from endometrial and lung cancer patients, archived in the Wales Cancer Bank. The latest results demonstrated the sensitivity of PointMan in detecting cfDNA mutations—BRAF (endometrial cancer) and EGFR (lung cancer). Based on the promise of these initial proof-of-concept results, EKF is now sponsoring an MSc studentship to further evaluate the use of PointMan to enrich mutant variants in cfDNA isolated from patients suffering from, or at risk of developing, gynecological cancers.

The ongoing project aims to correlate the presence and abundance of specific mutant variants of known endometrial and ovarian cancer biomarkers in cfDNA from blood samples of patients with established clinical diagnoses for these conditions. Ultimately, the results will establish whether these biomarkers provide a better diagnosis, or enhance current diagnostic tests.

The latest data from Swansea also compliment recent work undertaken using the "GILUPI CellCollector," a device for collecting circulating tumor cells (CTCs) directly from a patient’s blood stream. This highlighted the utility of a blood-based test and critically demonstrated that PointMan can even detect from only 3 mutant cells in a background of 1,000 wild type cells. A control PCR reaction was unable to achieve such sensitivity, which is important as it reflects the number of mutant cells in a typical patient sample.

Julian Baines, EKF’s CEO, commented, “This latest data-set from the Institute of Life Sciences (Swansea) and our MSc sponsorship marks a significant milestone in establishing the effectiveness of PointMan in the development of a blood test for various cancers. Having confirmed its particular sensitivity, we can now move onto the next stage of evaluation, working with greater numbers of patient samples to clearly establish a correlation between cfDNA mutation status and the development of various solid tumors.” PointMan’s extremely high sensitivity offers a unique advantage in the early detection, monitoring of disease progression, and assessing the efficacy of anticancer treatments—without the need for a tissue biopsy and related procedures. The PointMan portfolio currently includes products for: BRAF, KRAS, EGFR, NRAS, ESR1, and JAK2.

PointMan, a real-time PCR technology, is highly efficient in amplifying the target sequence of interest, while suppressing amplification of the wild-type sequence. The resulting sample is effectively enriched for the mutation, thereby having the potential to offer leading sensitivity in a wide variety of sample types, including whole blood.

Related Links:

EKF Molecular Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.